India Thyroid Disorder Market Summary

As per Market Research Future analysis, the India thyroid disorder market Size was estimated at 125.56 USD Million in 2024. The India thyroid disorder market is projected to grow from 130.17 USD Million in 2025 to 186.6 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 3.6% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The India thyroid disorder market is experiencing robust growth driven by increased awareness and advancements in treatment options.

Rising awareness and screening initiatives are significantly enhancing early detection of thyroid disorders.
Advancements in treatment options are expanding the therapeutic landscape for patients with thyroid conditions.
The integration of telemedicine is facilitating access to healthcare services for thyroid disorder management.
The increasing prevalence of thyroid disorders and government initiatives are key drivers propelling market growth.

Market Size & Forecast

2024 Market Size	125.56 (USD Million)
2035 Market Size	186.6 (USD Million)
CAGR (2025 - 2035)	3.67%

Major Players

AbbVie (US), Bristol-Myers Squibb (US), Eli Lilly and Company (US), Merck & Co. (US), Novartis (CH), Pfizer (US), Sanofi (FR), Takeda Pharmaceutical Company (JP), AstraZeneca (GB)

Our Impact

Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals

Partnering with 2000+ Global Organizations Each Year

30K+ Citations by Top-Tier Firms in the Industry

India Thyroid Disorder Market Trends

The thyroid disorder market is currently experiencing notable growth. This growth is driven by an increasing prevalence of thyroid-related conditions among the population. Factors such as lifestyle changes, dietary habits, and genetic predispositions contribute to the rising incidence of disorders like hypothyroidism and hyperthyroidism. Awareness campaigns and improved diagnostic techniques are enhancing detection rates, leading to more individuals seeking treatment. Furthermore, the healthcare infrastructure in India is evolving, with advancements in medical technology and increased access to healthcare services, which may facilitate better management of thyroid disorders. In addition, the thyroid disorder market is witnessing a surge in demand for innovative treatment options. The introduction of novel therapies and medications, alongside traditional treatment methods, appears to be reshaping patient care. Patients are increasingly inclined towards personalized medicine, which suggests a shift towards tailored treatment plans based on individual needs. This trend may lead to improved patient outcomes and satisfaction, as healthcare providers focus on delivering more effective and targeted therapies for thyroid disorders.

Rising Awareness and Screening

There is a growing emphasis on awareness campaigns aimed at educating the public about thyroid disorders. Increased screening initiatives are likely to lead to earlier diagnosis and treatment, potentially reducing the burden of advanced cases.

Advancements in Treatment Options

The thyroid disorder market is seeing a shift towards innovative treatment modalities. New medications and therapies are emerging, which may offer improved efficacy and safety profiles, catering to the diverse needs of patients.

Integration of Telemedicine

The integration of telemedicine into healthcare services is transforming patient access to care. This trend may enhance follow-up consultations and management of thyroid disorders, particularly in remote areas where healthcare resources are limited.

India Thyroid Disorder Market Drivers

Growing Geriatric Population

The increasing geriatric population in India is a significant factor influencing the thyroid disorder market. Older adults are more susceptible to thyroid disorders, particularly hypothyroidism and hyperthyroidism. As the demographic landscape shifts, with projections indicating that the elderly population will reach 300 million by 2050, the demand for thyroid-related healthcare services is expected to rise. This demographic trend may lead to a greater need for screening, diagnosis, and treatment options tailored to older patients. Consequently, the thyroid disorder market is likely to expand in response to the healthcare needs of this growing population segment.

Rising Demand for Personalized Medicine

The trend towards personalized medicine is emerging as a key driver in the thyroid disorder market. Patients are increasingly seeking tailored treatment plans that consider their unique genetic and biochemical profiles. This shift is prompting pharmaceutical companies to invest in research and development of targeted therapies for thyroid disorders. The market is likely to see a rise in the availability of personalized treatment options, which may improve patient adherence and outcomes. Additionally, the integration of genetic testing into routine clinical practice could further enhance the precision of thyroid disorder management, thereby expanding the market's potential.

Increasing Prevalence of Thyroid Disorders

The rising incidence of thyroid disorders in India is a crucial driver for the thyroid disorder market. Recent studies indicate that approximately 42 million individuals in India are affected by thyroid-related conditions, with hypothyroidism being the most prevalent. This growing patient population necessitates enhanced diagnostic and therapeutic solutions, thereby propelling market growth. the thyroid disorder market is expected to expand as healthcare providers focus on early detection and management of these conditions. Furthermore, the increasing awareness among the general public regarding thyroid health is expected to contribute to higher screening rates, which may lead to an uptick in demand for treatment options. As a result, the thyroid disorder market will experience significant growth in the coming years.

Government Initiatives and Healthcare Policies

Government initiatives aimed at improving healthcare access and awareness are pivotal in shaping the thyroid disorder market. The Indian government has implemented various health programs to address non-communicable diseases, including thyroid disorders. These initiatives often include subsidized screening and treatment options, which can enhance patient access to necessary healthcare services. Additionally, public health campaigns focused on educating the population about thyroid health are likely to increase early diagnosis rates. As a result, the thyroid disorder market may experience a surge in demand for diagnostic tests and treatment modalities, driven by supportive healthcare policies and increased funding for thyroid health initiatives.

Technological Advancements in Diagnostic Tools

advancements in diagnostic technologies significantly influence the thyroid disorder market. Innovations such as high-sensitivity thyroid function tests and imaging techniques have improved the accuracy and speed of diagnosis. These technological improvements facilitate early detection of thyroid disorders, which is essential for effective management. Moreover, the introduction of point-of-care testing devices allows for rapid assessment in various healthcare settings, potentially increasing patient compliance and follow-up. As diagnostic capabilities continue to evolve, the thyroid disorder market will benefit from enhanced testing options, leading to better patient outcomes and increased treatment uptake.

Market Segment Insights

By Type: Hypothyroidism (Largest) vs. Hyperthyroidism (Fastest-Growing)

In the India thyroid disorder market, the prevalence of hypothyroidism remains significant, capturing the largest share of the segment. This condition is characterized by an underactive thyroid gland, leading to a range of health complications. Conversely, hyperthyroidism is also prevalent but is recognized as the fastest-growing segment due to increased awareness, early diagnosis, and improved treatment options that enhance patient outcomes. The growth trends in this market are driven by various factors, including a growing aging population, lifestyle changes, and the rising incidence of autoimmune diseases. Healthcare providers are focusing on early detection and effective treatment strategies, which are likely to boost the market for both conditions. Advances in technology and increased access to healthcare services are expected to further propel the growth, particularly for hyperthyroidism treatments as they gain popularity among patients.

Hypothyroidism: Dominant vs. Hyperthyroidism: Emerging

Hypothyroidism is currently the dominant segment in the market, characterized by its widespread recognition and established treatment pathways. Patients commonly require lifelong management, which contributes to steady demand for thyroid hormone replacement therapies. On the other hand, hyperthyroidism is viewed as an emerging segment with a notably increasing diagnosis rate. Factors such as genetic predisposition and environmental triggers are pivotal in its rise. While treatment options for hyperthyroidism are expanding, including antithyroid medications and radioactive iodine, ongoing patient education and awareness campaigns are essential to enhance diagnosis and management. As healthcare systems evolve, both segments are poised for growth, with hypothyroidism maintaining its substantial market presence amidst the expanding hyperthyroid treatment landscape.

By Treatment: Medications (Largest) vs. Radioactive Iodine Therapy (Fastest-Growing)

In the India thyroid disorder market, the treatment segment consists of three key values: Medications, Surgery, and Radioactive iodine therapy. Among these, Medications hold the largest share, making it the most preferred treatment option for patients dealing with thyroid disorders. Surgery and Radioactive iodine therapy, while important, take up comparatively smaller market shares. This distribution indicates a strong reliance on pharmaceutical interventions, which are often seen as less invasive and more manageable by patients. Growth trends within the treatment segment reflect a rising demand for effective management of thyroid disorders with an increasing focus on Medications and Radioactive iodine therapy. The preference for Medications continues to dominate due to their accessibility and the ongoing development of new therapeutic drugs. Meanwhile, Radioactive iodine therapy is emerging as the fastest-growing option as advancements in treatment protocols and enhanced patient awareness drive its adoption, signaling an evolving landscape in treatment preferences among thyroid disorder patients.

Medications (Dominant) vs. Radioactive Iodine Therapy (Emerging)

Medications are the dominant force in the treatment segment due to their established efficacy and patient familiarity. They offer a range of options including hormone replacement therapies and antithyroid agents, catering to diverse patient needs. These treatments are typically more accessible and less invasive, making them the first line of defense against thyroid conditions. On the other hand, Radioactive iodine therapy is considered an emerging choice, particularly for hyperthyroidism and certain thyroid cancer patients. Its rapid growth can be attributed to increased recognition of its effectiveness and safety profile. As healthcare providers become more knowledgeable about this option, the adoption rates continue to rise, reflecting the shifting dynamics of treatment decisions in patients.

By Route of Administration: Oral (Largest) vs. Intravenous (Fastest-Growing)

In the India thyroid disorder market, the route of administration is primarily dominated by the oral segment, which accounts for a significant market share. This can be attributed to the higher acceptance and convenience of oral medications among patients, making it the preferred choice for a majority of thyroid disorder treatments. In contrast, the intravenous route, while holding a smaller share, is rapidly gaining traction due to advancements in medical technology and an increase in the number of healthcare facilities enhancing patient care. Growth trends within this segment indicate an increasing preference for the oral route, driven by factors such as patient convenience and ease of administration. However, the intravenous segment is quickly emerging as the fastest-growing, primarily fueled by the rising prevalence of severe thyroid disorders that require immediate therapeutic interventions. This trend is further supported by ongoing research and development aimed at improving intravenous formulations, making them more effective and appealing to healthcare providers.

Administration: Oral (Dominant) vs. Intravenous (Emerging)

The oral administration of medications is immensely popular in the India thyroid disorder market, positioning it as the dominant route due to its accessibility and patient compliance. Oral formulations, such as tablets and capsules, are widely accepted because they are easy to administer and carry less risk compared to injectable methods. On the other hand, intravenous administration is recognized as an emerging choice, particularly for patients facing severe thyroid conditions that necessitate immediate treatment. Although it represents a smaller portion of the market, intravenous administration is gaining attention due to advancements in delivery systems and the ability to offer rapid therapeutic effects, thereby enhancing treatment outcomes in critical scenarios.

By End-User: Hospitals (Largest) vs. Clinics (Fastest-Growing)

In the India thyroid disorder market, the distribution among end-user segments reveals that hospitals hold the largest share, primarily due to their capacity to provide comprehensive healthcare and specialized treatment for thyroid disorders. Meanwhile, clinics, while smaller in terms of overall market share, represent the fastest-growing segment, appealing to the increasing preference for outpatient care and personalized treatment plans. The growth trends for these segments are largely driven by escalating awareness of thyroid disorders and the rising demand for early diagnosis and treatment options. Hospitals are expanding their services to accommodate a growing patient base, while clinics are capitalizing on the trend towards convenience and accessibility, establishing themselves as essential providers in managing thyroid health effectively.

Hospitals (Dominant) vs. Clinics (Emerging)

Hospitals in the India thyroid disorder market play a dominant role by offering advanced treatment protocols and specialized care, benefiting from their extensive resources and multidisciplinary teams. They provide a full spectrum of diagnostic and therapeutic options to cater to a wide variety of thyroid disorders. On the other hand, clinics, emerging as a significant player, focus on streamlined, patient-centric approaches, often offering more affordable and accessible care. The convenience of local clinics is attracting more patients seeking timely diagnosis and treatment, which positions them as a crucial component of the healthcare landscape, complementing the services offered by hospitals.

Get more detailed insights about India Thyroid Disorder Market

Request Free Sample

Key Players and Competitive Insights

The thyroid disorder market in India is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and regional expansion. Key players such as AbbVie (US), Merck & Co. (US), and Novartis (CH) are actively pursuing strategies that enhance their market presence and operational efficiency. AbbVie (US) focuses on developing novel therapies, which positions it favorably in a market that demands advanced treatment options. Meanwhile, Merck & Co. (US) emphasizes strategic collaborations with local healthcare providers to improve patient access to its products, thereby enhancing its competitive edge. Novartis (CH) is also investing in digital health initiatives, which reflects a broader trend towards integrating technology into healthcare solutions, thus shaping the competitive dynamics of the market. The business tactics employed by these companies include localizing manufacturing and optimizing supply chains to reduce costs and improve service delivery. The market structure appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies like Pfizer (US) and Sanofi (FR) is significant, as they leverage their extensive distribution networks and brand recognition to maintain a competitive advantage. In October 2025, Pfizer (US) announced a partnership with a leading Indian biotechnology firm to co-develop a new thyroid medication aimed at addressing unmet medical needs in the region. This collaboration is strategically important as it not only enhances Pfizer's product portfolio but also allows for localized development, which could lead to faster regulatory approvals and market entry. Such partnerships are indicative of a trend where multinational corporations seek to leverage local expertise to navigate the complexities of the Indian healthcare landscape. In September 2025, Merck & Co. (US) launched a digital platform designed to facilitate patient engagement and education regarding thyroid disorders. This initiative is crucial as it aligns with the growing emphasis on patient-centric care, potentially improving treatment adherence and outcomes. By investing in digital solutions, Merck is likely positioning itself as a leader in the integration of technology within the healthcare sector, which could enhance its competitive standing. In August 2025, Novartis (CH) expanded its manufacturing capabilities in India, focusing on the production of generic thyroid medications. This move is significant as it not only addresses the rising demand for affordable treatment options but also strengthens Novartis's supply chain resilience. By increasing local production, the company may reduce its dependency on imports, thereby mitigating risks associated with global supply chain disruptions. As of November 2025, current trends in the thyroid disorder market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in treatment protocols. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in enhancing innovation and market reach. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on technological advancements, innovative treatment solutions, and reliable supply chains. This shift underscores the importance of adaptability and forward-thinking strategies in maintaining a competitive edge in the dynamic healthcare landscape.

Key Companies in the India Thyroid Disorder Market include

Industry Developments

In recent months, the India Thyroid Disorder Market has seen significant developments, including increased awareness and diagnosis rates among the population. Noteworthy is the growth of companies like Lupin, Sun Pharmaceutical, and Dr. Reddy's Laboratories, which have strengthened their portfolios in thyroid medications through Research and Development initiatives and strategic marketing campaigns. In July 2023, Sun Pharmaceutical expanded its distribution channels for its thyroid formulations, effectively reaching a larger patient base.

Additionally, the market has been influenced by an upturn in health awareness programs orchestrated by governmental health agencies, leading to an uptick in diagnosed cases of hypothyroidism and hyperthyroidism. In terms of mergers and acquisitions, there have been no notable announcements relating directly to major companies such as Pfizer, Merck, or GSK specifically within the thyroid segment in India. However, the overall valuation of the market is projected to grow, driven by the aging population and increasing prevalence of thyroid disorders. Furthermore, the emergence of telehealth services has facilitated better access to endocrinologists, fostering patient engagement and adherence to treatments.

Future Outlook

India Thyroid Disorder Market Future Outlook

The Thyroid Disorder Market in India is projected to grow at a 3.67% CAGR from 2025 to 2035, driven by increasing prevalence and advancements in treatment options.

New opportunities lie in:

Development of telehealth platforms for remote patient monitoring.
Investment in AI-driven diagnostic tools for early detection.
Expansion of personalized medicine approaches tailored to individual patient profiles.

By 2035, the market is expected to achieve substantial growth, reflecting evolving healthcare needs.

Market Segmentation

India Thyroid Disorder Market Type Outlook

Hypothyroidism
Hyperthyroidism

India Thyroid Disorder Market End-User Outlook

Clinics
Hospitals
Others

India Thyroid Disorder Market Treatment Outlook

Medications
Surgery
Radioactive iodine therapy

India Thyroid Disorder Market Route of Administration Outlook

Intravenous
Oral
Other

Report Scope

MARKET SIZE 2024	125.56(USD Million)
MARKET SIZE 2025	130.17(USD Million)
MARKET SIZE 2035	186.6(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)	3.67% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Million
Key Companies Profiled	AbbVie (US), Bristol-Myers Squibb (US), Eli Lilly and Company (US), Merck & Co. (US), Novartis (CH), Pfizer (US), Sanofi (FR), Takeda Pharmaceutical Company (JP), AstraZeneca (GB)
Segments Covered	Type, Treatment, Route of Administration, End-User
Key Market Opportunities	Advancements in personalized medicine and digital health solutions enhance management of thyroid disorders.
Key Market Dynamics	Rising prevalence of thyroid disorders drives demand for innovative diagnostics and treatment solutions in the market.
Countries Covered	India

FAQs

What was the overall market valuation of the thyroid disorder market in 2024?

The overall market valuation was $125.56 Million in 2024.

What is the projected market valuation for the thyroid disorder market by 2035?

The projected market valuation for 2035 is $186.6 Million.

What is the expected CAGR for the thyroid disorder market during the forecast period 2025 - 2035?

The expected CAGR for the market during the forecast period 2025 - 2035 is 3.67%.

Which companies are considered key players in the thyroid disorder market?

Key players include AbbVie, Bristol-Myers Squibb, Eli Lilly and Company, Merck & Co., Novartis, Pfizer, Sanofi, Takeda Pharmaceutical Company, and AstraZeneca.

What are the market segments for thyroid disorders based on type?

The market segments based on type include Hypothyroidism, valued between $80.0 Million and $120.0 Million, and Hyperthyroidism, valued between $45.56 Million and $66.6 Million.

What treatment options are available in the thyroid disorder market?

Treatment options include Medications, valued between $75.0 Million and $110.0 Million, Surgery, valued between $30.0 Million and $45.0 Million, and Radioactive iodine therapy, valued between $20.56 Million and $31.6 Million.

What routes of administration are utilized in the thyroid disorder market?

The routes of administration include Intravenous, valued between $15.0 Million and $22.0 Million, Oral, valued between $85.0 Million and $130.0 Million, and Other, valued between $25.56 Million and $34.6 Million.

What are the end-user segments in the thyroid disorder market?

End-user segments include Clinics, valued between $30.0 Million and $45.0 Million, Hospitals, valued between $70.0 Million and $100.0 Million, and Others, valued between $25.56 Million and $41.6 Million.

How does the thyroid disorder market in India compare to global trends?

While specific global comparisons are not provided, the growth trajectory in India, with a projected CAGR of 3.67%, suggests a robust market potential.

What factors may influence the growth of the thyroid disorder market in India?

Factors influencing growth may include increasing awareness of thyroid disorders, advancements in treatment options, and the expanding healthcare infrastructure.

Author

Author

Satyendra Maurya

Research Analyst

An accomplished research analyst with high proficiency in market forecasting, data visualization, competitive benchmarking, and others. He holds a pronounced track record in research and consulting projects for sectors such as life sciences, medical devices, and healthcare IT. His capabilities in qualitative and quantitative analysis have resulted in positive client outcomes. Working on niche market trends, opportunities, sales, and forecasted value is part of his skill set.

Co-Author

Garvit Vyas

Vice President - Operations

Garvit Vyas is a Research Analyst with experience in working across multiple industry domains in the market research sector. Over the past four years, he has been actively involved in analyzing diverse markets, gathering industry insights, and contributing to the development of comprehensive research reports. His work includes studying market trends, evaluating competitive landscapes, and supporting data-driven business insights. In the early phase of his career, Garvit worked on cross-domain research projects, which helped him build a strong foundation in market analysis, data interpretation, and industry intelligence across various sectors. Later, he transitioned into the Quality Control (QC) function, where he focuses on reviewing and refining research reports and marketing collaterals to ensure accuracy, consistency, and high editorial standards. His responsibilities include validating research data, improving report structure, and maintaining the overall quality of published content. Garvit is committed to maintaining strong research integrity and delivering reliable insights that support informed business decision-making.

Get In Touch

Leave a Comment